Sign inJoin waitlistJoin the waitlist

MW

Matthew Wieduwilt

Co-Associate Leader · Wake Forest University Baptist Medical Center

Credentials: · · · · ·

History

Wake Forest University Baptist Medical Center
Present
Wake Forest University Baptist Medical Center
Present

University of California
2008–2011
Internal Medicine
University of California
2005–2008
Univ of Texas Southwestern Med Sch at Dallas
2001–2005

Research

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid…
Journal of Clinical Oncology · 2018 · 802 citations
The epidermal growth factor receptor family: biology driving targeted therapeutics
Review · Cellular and Molecular Life Sciences · 2008 · First of 2 authors · 561 citations
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2019 · 359 citations

Geoffrey Uy
13 papers
Richard Stone
11 papers
Anjali Advani
10 papers
Mark Litzow
10 papers
MT
Martin Tallman
9 papers
Gary Schiller
8 papers
JL
Jeffrey Lancet
8 papers
Amir Fathi
7 papers
Marcos de Lima
7 papers
Aaron Logan
6 papers
Dale Bixby
6 papers
Ryan Mattison
6 papers

Clinical trials

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2019–2027
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2010–2021
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
Study chair · Terminated · Phase 2
University of California, San Diego
2020–2022
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027